AIM ImmunoTech (NYSEAMERICAN:AIM) Trading 4.5% Higher – Here’s What Happened

Shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) rose 4.5% during mid-day trading on Friday . The company traded as high as $1.02 and last traded at $0.9589. Approximately 1,692,022 shares traded hands during trading, a decline of 83% from the average daily volume of 9,676,714 shares. The stock had previously closed at $0.9180.

Wall Street Analysts Forecast Growth

Separately, Zacks Research downgraded AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, AIM ImmunoTech presently has a consensus rating of “Buy”.

AIM ImmunoTech Trading Up 4.5%

The firm has a market cap of $3.15 million, a price-to-earnings ratio of -0.05 and a beta of 1.26. The firm’s 50-day moving average is $1.03 and its 200-day moving average is $1.63.

Institutional Investors Weigh In On AIM ImmunoTech

A number of institutional investors and hedge funds have recently made changes to their positions in AIM. Corient Private Wealth LLC bought a new stake in AIM ImmunoTech during the 2nd quarter worth approximately $87,000. DRW Securities LLC lifted its holdings in shares of AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after purchasing an additional 26,254 shares in the last quarter. Finally, Sabby Management LLC bought a new position in shares of AIM ImmunoTech in the third quarter valued at approximately $79,000. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.